Gilteritinib with chemotherapy for FLT3-ITD positive AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 60 years old.
- You have been newly diagnosed with a type of AML called FLT3-ITD positive.
- Your general health is good (ECOG score 0, 1, or 2).
- Your liver and kidney function tests are within certain limits.
- You are not pregnant or breastfeeding.
- You do not have active serious infections, other cancers, or certain heart/lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy (FLAI) and a targeted drug (Gilteritinib) for adults with acute myeloid leukemia (AML) that has a specific genetic change called FLT3. It aims to see if the combo works better than standard treatment.
This trial tests a new combination of three drugs (gilteritinib, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) that no longer responds to azacitidine and venetoclax. The goal is to see if this triple therapy can help achieve remission and improve outcomes.
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
This study looks at how well new AML medicines work in everyday medical practice, outside of clinical trials. If you are starting a newer AML drug like gilteritinib, an IDH inhibitor, oral azacytidine, or others, you may be able to join.
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
This trial tests adding a targeted drug called gilteritinib to a standard two-drug combination (venetoclax and azacitidine) for people with a specific genetic change (FLT3 mutation) in their acute myeloid leukemia (AML). The goal is to see if the three drugs together work better than the two alone, for patients who cannot tolerate strong chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.